{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:28:22Z","timestamp":1774960102219,"version":"3.50.1"},"reference-count":8,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"DOI":"10.1182\/blood.2022018936","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:31:52Z","timestamp":1680190312000},"page":"1502-1503","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The cat-and-mouse game of BTK inhibition"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0518-9554","authenticated-orcid":false,"given":"Ana","family":"Portelinha","sequence":"first","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[{"name":"1Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"13","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in\u00a0vivo activity in CLL patient-derived xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"2023033015312872400_","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"e127566","DOI":"10.1172\/jci.insight.127566","article-title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity","volume":"4","author":"Wang","year":"2019","journal-title":"JCI Insight"},{"issue":"8","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.37349\/etat.2020.00009","article-title":"Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors","volume":"1","author":"Arthur","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"issue":"4","key":"2023033015312872400_","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1502\/2040683\/blood_bld-2022-018936-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1502\/2040683\/blood_bld-2022-018936-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,2]],"date-time":"2023-04-02T11:49:30Z","timestamp":1680436170000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/13\/1502\/495013\/The-cat-and-mouse-game-of-BTK-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":8,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022018936","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}